APOE-CLCN3 Fusion FISH Probe
The APOE-CLCN3 Fusion FISH Probe is used to confirm a fusion of the APOE and CLCN3 genes. The fusion of the APOE and CLCN3 genes has been associated with Adrenocortical Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| APOE-CLCN3-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-RERE | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-REOR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-REGO | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-REGR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-OROR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GORE | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GROR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| APOE-CLCN3-20-AQAQ | 20 (40 μL) | 200 μL |
|
APOE Gene Summary
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]
Gene Name: Apolipoprotein E
Chromosome: CHR19: 45409038 -45412650
Locus: 19q13.32
CLCN3 Gene Summary
This gene encodes a member of the voltage-gated chloride channel (ClC) family. The encoded protein is present in all cell types and localized in plasma membranes and in intracellular vesicles. It is a multi-pass membrane protein which contains a ClC domain and two additional C-terminal CBS (cystathionine beta-synthase) domains. The ClC domain catalyzes the selective flow of Cl- ions across cell membranes, and the CBS domain may have a regulatory function. This protein plays a role in both acidification and transmitter loading of GABAergic synaptic vesicles, and in smooth muscle cell activation and neointima formation. This protein is required for lysophosphatidic acid (LPA)-activated Cl- current activity and fibroblast-to-myofibroblast differentiation. The protein activity is regulated by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) in glioma cells. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]
Gene Name: Chloride Voltage-gated Channel 3
Chromosome: CHR4: 170541671 -170644338
Locus: 4q33
Gene Diseases
The APOE CLCN3 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Adrenocortical Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|